Head-To-Head Review: OnKure Therapeutics (OKUR) versus Its Competitors

OnKure Therapeutics (NASDAQ:OKUR) is one of 1,049 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare OnKure Therapeutics to related companies based on the strength of its institutional ownership, dividends, profitability, risk, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for OnKure Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	0	0	2	1	3.33
OnKure Therapeutics Competitors	7622	20908	48546	1193	2.55

OnKure Therapeutics presently has a consensus target price of $37.50, indicating a potential upside of 142.25%. As a group, “Pharmaceutical preparations” companies have a potential upside of 71.63%. Given OnKure Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe OnKure Therapeutics is more favorable than its peers.

Institutional and Insider Ownership

91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 17.9% of OnKure Therapeutics shares are held by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares OnKure Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-51.17%	-47.11%
OnKure Therapeutics Competitors	-3,610.16%	-274.38%	-39.07%

Volatility and Risk

OnKure Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, OnKure Therapeutics’ peers have a beta of 1.00, indicating that their average share price is 0% more volatile than the S&P 500.

Earnings & Valuation

This table compares OnKure Therapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OnKure Therapeutics	N/A	-$77.39 million	-1.27
OnKure Therapeutics Competitors	$1.72 billion	$154.84 million	-5.58

OnKure Therapeutics’ peers have higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

OnKure Therapeutics beats its peers on 9 of the 13 factors compared.

About OnKure Therapeutics

Reneo Pharmaceuticals Inc.is a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Inc.is based in SAN DIEGO.